Liver Metastases
Conditions
Keywords
Stereotactic Body Radiation Therapy (SBRT), standard uptake value (SUV)
Brief summary
This is a phase I dose escalation study. Dose escalation will be via the traditional up and down scheme. SBRT: Patients will receive one of the following radiation regimens: * 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. * 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. * 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
Detailed description
Prior to enrollment all patients will be evaluated with a physical exam, review of pathology and laboratory values to confirm diagnosis, and baseline imaging studies. Accelerator Physicians will treat with a stereotactic radiosurgery system using 6MV photons to deliver stereotactic body radiotherapy. Doses Patients will receive a total dose ranging from 50-75 Gy in 5 fractions (10-15 Gy/fx). Dose escalation will be via the traditional up and down scheme. In determining the radiation dose and fractionation scheme for this protocol, we used the linear-quadratic formalism for radiation cell killing to equate schemes that vary the dose/fraction and number of fractions. This concept of biologically equivalent dose (BED) states that the total effect is given by: nd x (1 + d/(alpha-beta ratio)) where n is the # of fractions and d is the dose/fraction. The alpha-beta ratio characterizes the radiation response of a particular tissue; a higher value is indicative of a tissue that responds acutely to the effects of radiation. Due to their highly proliferative nature, most tumors fall into this category. This final dose scheme (total dose 75 Gy) is biologically equivalent to the previously studied doses in the literature (60 Gy in 3 fractions), meaning the first two sets of patients will be treated to a radiobiologically smaller (and likely safer) dose. We would favor treating in five fractions, as opposed to three, to allow more repair of normal tissue, reoxygenation of tumor cells, and redistribution of tumor cells to more radiosensitive parts of the cell cycle. Using a smaller fraction size, 10-15 Gy compared to 20 Gy, will also help reduce late effects of radiation therapy. SBRT treatment will be given on an every other day schedule, excluding weekends. The prescription dose will be prescribed to the isodose line best encompassing the planning target volume (PTV) depending on the volume of tumor (HCC). Localization, immobilization, and simulation Within 5 - 10 days after fiducial placement, pPatients will undergo 4D FDG-PET/CT simulation with the goal of evaluating tumor motion to allow for gated treatment when indicated. This goal will be accomplished by using the Real-time Position Management (RPM) system (Varian Medical Systems, Palo Alto, CA) to create a retrospective 4D CT scan. Following the institutional protocol, a helical CT scan and a 4D positron emission tomography (PET) scan with a patient with body immobilization device will be acquired. A patient will not eat or drink anything for four hours before the PET scan. Before the PET scan, blood sample will be taken from either a finger stick or a vein in the arm to check the sugar level. An injection of a small amount of a radioactive drug called FDG ( \[F18\] fluorodeoxyglucose) which is a chemical similar to sugar will be administered into a vein in the arm or hand. Approximately 45 to 60 minutes after the injection of FDG, the patient will be asked to urinate (to empty the bladder). The patient will be set up in the PET/CT scanner using a vacuum cushion for immobilization in the supine position with feet tied and hands across the chest or above the head. There will also be a respiration-monitoring device called a marker block placed 5cm below the patient's xyphoid process. An infrared camera at the foot of the CT table will capture the images of the marker block and relay them to the RPM computer, which in turn will translate the images into a respiratory pattern. The audio coach (which instructs the patient in regulating breathing) will be calibrated to both patient comfort and time of expiration, inspiration, and full breathing cycle. The placing of the patient in a body immobilization device will take about 10-15 minutes. The patient will need to lie still for about 30 minutes before the completion of the 4D PET scan. The PET/CT scanner will then be programmed to acquire a retrospective 4D CT scan with a set of images for each phase of the breathing cycle. This scan will take place immediately after the PET scan. It will take around 5-10 minutes. The physician or physicist will then select the number of breathing phases to use while the software program selects the best image for each selected breathing phase. The entire FDG-PET/CT scan procedure is expected to take about 2 hours. Treatment Planning Treatment planning will be carried out using the planning station for the radiosurgery equipment being used for treatment. The gross tumor volume (GTV) will be contoured on the fused image set. Two GTV volumes will be contoured; the gross tumor as seen on CT alone and the gross tumor corresponding to FDG avidity. No margins will be added for clinical target volume (CTV), but custom margins will be added for the planning target volume (PTV) based on the findings of the 4D FDG-PET/CT motion study assessment. The treatment will be prescribed to the isodose line that best covers the planning target volume, which will typically be the 80% isodose line. Treatment Delivery SBRT will take place within 14 days of the treatment planning scan. The planning data containing the coordinates of tumor isocenter, the external infrared markers, and the implanted markers are transferred to the appropriate platform depending on the treating machine. If the patient meets the criteria of gating technique then treatment delivery will be accomplished using the appropriate gating technology. Depending on the technology used external infrared markers attached to the patient's skin or a marker block placed on the patient's chest is used to determine the breathing pattern. The size of beam-on window will be determined based on the target motion as detected by the 4D FDG-PET/CT scan. The threshold for gated treatment delivery is determined based upon the target motion due to respiration. The daily initial positioning during treatment delivery will be performed using lasers and skin marks and infrared optical markers as appropriate. The target isocenter will be verified using daily imaging. Depending on the platform used, the moving target will be positioned within the beam under infrared and/or image guidance
Interventions
RADIATIONStereotactic Body Radiation Therapy
SBRT: Patients will receive one of the following radiation regimens: * 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. * 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. * 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
Sponsors
Susannah Ellsworth
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients ≥ 18 years of age * A life expectancy of at least 6 months with a Karnofsky performance status of at least 70 * The target lesion(s) can be accurately measured in at least one dimension according to RECIST and must have a maximum tumor volume of ≤ 100 cm3 * No prior radiotherapy to the upper abdomen * Previous systemic chemotherapy or non-radiation local therapy (such as surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) is allowed. The lesion must however have shown criteria of progression based on RECIST. Local therapy must be completed at least 4 weeks prior to the baseline scan. This is to create a safer treatment environment and to help determine the effect of treatment by SBRT alone. Patients will be allowed to go onto appropriate systemic therapy, as determined by their medical oncologist, 2 weeks following delivery of SBRT * Patients with resectable disease will be eligible for participation if they have comorbidities precluding surgery or refuse to undergo an operation * Cirrhotic status of Child-Pugh class A or B * Patients can have extra-hepatic disease, provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with surgery, ablative radiation therapy, or US Food and Drug Administration-approved first- or second-line systemic therapy regimens * Patient's will have no evidence of gross vascular invasion. * Patients will have no more than 3 distinct lesions, all being ≤ 3cm in greatest dimension, OR 1 lesion ≤ 6cm in greatest dimension * Platelet count ≥ 60 x 109/L, Hemoglobin ≥ 8.5 g/dL, WBC ≥ 2000/μL International normalized ratio (INR) must be ≤ 2.3. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists * Other baseline labs must meet the following criteria: total bilirubin \< 3mg/dl, albumin\> 2.5mg/dl, and liver enzymes less than three times the upper limit of normal. Creatinine must also be \< 1.8mg/dl or a creatinine clearance \> 50ml/min * Must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts
Exclusion criteria
* Renal failure requiring hemo- or peritoneal dialysis * Uncontrolled inter-current illness including, but not limited to ongoing or active infection (\> grade 2 National Cancer Institute \[NCI\]-Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0), congestive heart failure (\> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study . Myocardial infarction more than 6 months prior to study entry is permitted * A history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement * History of an active connective tissue disorder * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * Pregnant or breast-feeding patients are excluded from this study because abdominal radiation therapy has potential for teratogenic and/or abortifacient effects * Portal vein occlusion * Extensive liver tumor burden, defined as more than 75% of the liver. * Patients with primary tumor histology of lymphoma, leukemia, or germ cell tumor * Patients with hepatocellular carcinoma will be excluded from this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) | Up to 16 Months | MTD as determined by dose limiting toxicities (DLT), defined as any grade III stomach, bowel, liver, or spinal cord toxicity, or any grade IV toxicity per RTOG criteria. Only toxicities observed prior to 7 months after the last fraction of radiation were considered. The MTD is the highest dose level at which no more than 1 of 6 treated patients experiences a DLT. |
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Up to 16 Months | Dose limiting toxicity (DLT) will be defined as any grade III stomach, bowel, liver, or spinal cord toxicity, or any grade IV toxicity as defined by the Radiation Therapy Oncology Group (RTOG). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| FACT-G - Health Related Quality of Life (HRQL) Over Time | 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months | Health related quality of life associated with this SBRT will be assessed over time using the FACT-G assessment tool, a self-administered questionnaire that measures quality of life within the prior 7 days in patients being treated for cancer. The tool has 27 items with a 5-point Likert-type scale, (0 = Not at all to 5 = Very Much). Subscales include Physical Well-Being max score=28), Social/Family Well-Being (max score=28), Emotional Well-Being (max score=24), Functional Well-Being (max score=28). Total scores range from 0 to 108. Questions are phrased so that higher numbers indicate a better health state, with some items reverse-scored. |
| Local Control | Up to 6 years and 4 months (study population) | Proportion of treated patients with stable disease (SD), partial response (PR), or complete response (CR) in the target lesion(s) per Response Evaluation Criteria in Solid Tumors (RECIST) in the target lesion(s) at one-year post-treatment. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. All lymph nodes must be non-pathological in size (\<10mm short axis); PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| FACT-Hep-Trial Outcome Index (TOI) | 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months | Trial Outcome Index (TOI), the sum of the physical and functional well-being subscales and the additional concerns subscale is calculated. The TOI is a commonly used endpoint in clinical trials because it is responsive to change, whereas the social/family and emotional well-being subscale scores do not change as quickly over time or have as great of change subsequent to pharmacological treatment. The FACT-Hep is part of the Functional Assessment of Chronic Illness Therapy (FACIT 13) measurement system and includes the FACT-General (FACT-G) and an 18-item module specifically designed for patients diagnosed with hepatobiliary carcinomas with domain scores ranging from 0-32. FACT-Hep questions are scored using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Total Index scores range from 0 to 128. Higher scores are associated with better QoL or fewer symptoms. |
| Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) subscale was used to assess health-related quality of life associated with SBRT. The FACT-Hep is part of the Functional Assessment of Chronic Illness Therapy (FACIT; 13) measurement system and includes the FACT-General (FACT-G) and an 8-item module specifically designed for patients diagnosed with hepatobiliary carcinomas. FACT-Hep questions are scored using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much), with overall scores ranging from 0-32. Questions are phrased so that higher numbers indicate a better health state, with some items reverse-scored. |
| Local Response Rate | Up to 6 years and 4 months (study population) | Proportion of patients who experience local partial response (PR), or complete response (CR) in the target lesion(s) per Response Evaluation Criteria in Solid Tumors (RECIST) at any point in the first year of follow-up. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SBRT - 50 Gy Stereotactic Body Radiation Therapy: SBRT:
Patients received 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. | 3 |
| SBRT - 60 Gy Stereotactic Body Radiation Therapy: SBRT:
Patients received 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. | 6 |
| Total | 9 |
Baseline characteristics
| Characteristic | SBRT - 50 Gy | SBRT - 60 Gy | Total |
|---|---|---|---|
| Age, Continuous | 66.0 years | 68.0 years | 66.0 years |
| ECOG Performance Score ECOG = 1 | 1 participants | 0 participants | 1 participants |
| ECOG Performance Score Unknown | 2 participants | 6 participants | 8 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 6 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Karnofsky Score of Performance Status Karnofsky Score = 100 | 1 participants | 0 participants | 1 participants |
| Karnofsky Score of Performance Status Karnofsky Score = 70 | 1 participants | 1 participants | 2 participants |
| Karnofsky Score of Performance Status Karnofsky Score = 90 | 0 participants | 5 participants | 5 participants |
| Karnofsky Score of Performance Status Unknown | 1 participants | 0 participants | 1 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 6 Participants | 8 Participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 6 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 6 |
| other Total, other adverse events | 2 / 3 | 5 / 6 |
| serious Total, serious adverse events | 0 / 3 | 0 / 6 |
Outcome results
Primary
Maximum Tolerated Dose (MTD)
MTD as determined by dose limiting toxicities (DLT), defined as any grade III stomach, bowel, liver, or spinal cord toxicity, or any grade IV toxicity per RTOG criteria. Only toxicities observed prior to 7 months after the last fraction of radiation were considered. The MTD is the highest dose level at which no more than 1 of 6 treated patients experiences a DLT.
Time frame: Up to 16 Months
Population: All patients that received study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Maximum Tolerated Dose (MTD) | 60 Gy |
Primary
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
Dose limiting toxicity (DLT) will be defined as any grade III stomach, bowel, liver, or spinal cord toxicity, or any grade IV toxicity as defined by the Radiation Therapy Oncology Group (RTOG).
Time frame: Up to 16 Months
Population: All patients that received study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| SBRT - 60 Gy | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
Secondary
FACT-G - Health Related Quality of Life (HRQL) Over Time
Health related quality of life associated with this SBRT will be assessed over time using the FACT-G assessment tool, a self-administered questionnaire that measures quality of life within the prior 7 days in patients being treated for cancer. The tool has 27 items with a 5-point Likert-type scale, (0 = Not at all to 5 = Very Much). Subscales include Physical Well-Being max score=28), Social/Family Well-Being (max score=28), Emotional Well-Being (max score=24), Functional Well-Being (max score=28). Total scores range from 0 to 108. Questions are phrased so that higher numbers indicate a better health state, with some items reverse-scored.
Time frame: 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months
Population: All treated patients that completed QoL surveys.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | Post completion of RX Therapy | 107.0 score on a scale | — |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | 3-5 months post final Rx | 86.5 score on a scale | Standard Deviation 6.4 |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | Initial Rx Therapy | 82.6 score on a scale | Standard Deviation 35.9 |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | 18-20 months post final Rx | 78.0 score on a scale | Standard Deviation 0 |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | 6-8 months post final Rx | 87.0 score on a scale | — |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | 1-2 months post final Rx | 69.0 score on a scale | Standard Deviation 5.7 |
| All Participants | FACT-G - Health Related Quality of Life (HRQL) Over Time | Screening | 90.3 score on a scale | Standard Deviation 15 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 9-11 months post final Rx | 80.4 score on a scale | Standard Deviation 21.7 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 12-14 months post final Rx | 84.7 score on a scale | Standard Deviation 16.1 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 15-17 months post final Rx | 71.0 score on a scale | — |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 18-20 months post final Rx | 74.5 score on a scale | Standard Deviation 17.7 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 21-23 months post final Rx | 69.0 score on a scale | Standard Deviation 9.9 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 24-26 months post final Rx | 69.0 score on a scale | — |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | Screening | 88.0 score on a scale | Standard Deviation 16.3 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | Initial Rx Therapy | 82.5 score on a scale | Standard Deviation 23 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | Post completion of RX Therapy | 91.0 score on a scale | Standard Deviation 14.7 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 1-2 months post final Rx | 78.0 score on a scale | Standard Deviation 20.9 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 3-5 months post final Rx | 83.1 score on a scale | Standard Deviation 17.4 |
| SBRT - 60 Gy | FACT-G - Health Related Quality of Life (HRQL) Over Time | 6-8 months post final Rx | 85.1 score on a scale | Standard Deviation 17 |
Secondary
FACT-Hep-Trial Outcome Index (TOI)
Trial Outcome Index (TOI), the sum of the physical and functional well-being subscales and the additional concerns subscale is calculated. The TOI is a commonly used endpoint in clinical trials because it is responsive to change, whereas the social/family and emotional well-being subscale scores do not change as quickly over time or have as great of change subsequent to pharmacological treatment. The FACT-Hep is part of the Functional Assessment of Chronic Illness Therapy (FACIT 13) measurement system and includes the FACT-General (FACT-G) and an 18-item module specifically designed for patients diagnosed with hepatobiliary carcinomas with domain scores ranging from 0-32. FACT-Hep questions are scored using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Total Index scores range from 0 to 128. Higher scores are associated with better QoL or fewer symptoms.
Time frame: 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months
Population: All patients on study that completed QoL surveys
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | After completion of final Rx | 126.0 score on a scale | — |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | 03-05 months post final Rx | 101.0 score on a scale | Standard Deviation 4.2 |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | Initial Rx therapy session | 107.0 score on a scale | Standard Deviation 25.5 |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | 18-20 months post final Rx | 103.0 score on a scale | — |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | 06-08 months post final Rx | 117.0 score on a scale | — |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | 01-02 months post final Rx | 92.5 score on a scale | Standard Deviation 10.6 |
| All Participants | FACT-Hep-Trial Outcome Index (TOI) | Screening | 108.3 score on a scale | Standard Deviation 13.7 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 09-11 months post final Rx | 94.0 score on a scale | Standard Deviation 24.8 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 12-14 months post final Rx | 99.8 score on a scale | Standard Deviation 20.1 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 15-17 months post final Rx | 73.5 score on a scale | — |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 18-20 months post final Rx | 85.0 score on a scale | Standard Deviation 18.4 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 21-23 months post final Rx | 83.5 score on a scale | Standard Deviation 6.4 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 24-26 months post final Rx | 83.0 score on a scale | — |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | Screening | 106.0 score on a scale | Standard Deviation 17.6 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | Initial Rx therapy session | 98.5 score on a scale | Standard Deviation 29 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | After completion of final Rx | 104.0 score on a scale | Standard Deviation 21.4 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 01-02 months post final Rx | 90.4 score on a scale | Standard Deviation 27.2 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 03-05 months post final Rx | 92.5 score on a scale | Standard Deviation 16.3 |
| SBRT - 60 Gy | FACT-Hep-Trial Outcome Index (TOI) | 06-08 months post final Rx | 106.0 score on a scale | Standard Deviation 14.8 |
Secondary
Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time
Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) subscale was used to assess health-related quality of life associated with SBRT. The FACT-Hep is part of the Functional Assessment of Chronic Illness Therapy (FACIT; 13) measurement system and includes the FACT-General (FACT-G) and an 8-item module specifically designed for patients diagnosed with hepatobiliary carcinomas. FACT-Hep questions are scored using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much), with overall scores ranging from 0-32. Questions are phrased so that higher numbers indicate a better health state, with some items reverse-scored.
Time frame: 1-2 months, 3-5 months, 6-8 months, 9-11 months,12-14 months,15-17 months, 18-20 months, 21-23 months, 24-26 months
Population: All patients on study that completed QoL surveys
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Post completion of RX Therapy | 31.0 score on a scale | — |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 3-5 months post final Rx | 25.0 score on a scale | Standard Deviation 0 |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Initial Rx Therapy | 29.5 score on a scale | Standard Deviation 3.5 |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 18-20 months post final Rx | 23.0 score on a scale | — |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 6-8 months post final Rx | 29.0 score on a scale | — |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 1-2 months post final Rx | 24.5 score on a scale | Standard Deviation 2.1 |
| All Participants | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Screening | 27.0 score on a scale | Standard Deviation 5 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 9-11 months post final Rx | 24.2 score on a scale | Standard Deviation 5.7 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 12-14 months post final Rx | 24.2 score on a scale | Standard Deviation 4.6 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 15-17 months post final Rx | 18.0 score on a scale | — |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 18-20 months post final Rx | 22.0 score on a scale | Standard Deviation 4.2 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 21-23 months post final Rx | 22.5 score on a scale | Standard Deviation 0.7 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 24-26 months post final Rx | 21.0 score on a scale | — |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Screening | 27.2 score on a scale | Standard Deviation 4.6 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Initial Rx Therapy | 24.5 score on a scale | Standard Deviation 8.2 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | Post completion of RX Therapy | 25.3 score on a scale | Standard Deviation 5.8 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 1-2 months post final Rx | 21.2 score on a scale | Standard Deviation 7.7 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 3-5 months post final Rx | 24.3 score on a scale | Standard Deviation 5.8 |
| SBRT - 60 Gy | Functional Assessment of Cancer Therapy-Hepatobiliary Index (FSHI) Over Time | 6-8 months post final Rx | 26.7 score on a scale | Standard Deviation 4.6 |
Secondary
Local Control
Proportion of treated patients with stable disease (SD), partial response (PR), or complete response (CR) in the target lesion(s) per Response Evaluation Criteria in Solid Tumors (RECIST) in the target lesion(s) at one-year post-treatment. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. All lymph nodes must be non-pathological in size (\<10mm short axis); PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Up to 6 years and 4 months (study population)
Population: All patients treated per protocol and radiologically evaluable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Local Control | Complete Response | 1 Participants |
| All Participants | Local Control | Partial Response | 0 Participants |
| All Participants | Local Control | Stable Disease | 1 Participants |
| SBRT - 60 Gy | Local Control | Complete Response | 1 Participants |
| SBRT - 60 Gy | Local Control | Partial Response | 3 Participants |
| SBRT - 60 Gy | Local Control | Stable Disease | 1 Participants |
Secondary
Local Response Rate
Proportion of patients who experience local partial response (PR), or complete response (CR) in the target lesion(s) per Response Evaluation Criteria in Solid Tumors (RECIST) at any point in the first year of follow-up. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 6 years and 4 months (study population)
Population: All patients treated per protocol and radiologically evaluable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Local Response Rate | Partial Response | 0 Participants |
| All Participants | Local Response Rate | Complete Response | 1 Participants |
| SBRT - 60 Gy | Local Response Rate | Partial Response | 3 Participants |
| SBRT - 60 Gy | Local Response Rate | Complete Response | 1 Participants |